Details of the Drug

General Information of Drug (ID: DMFOVSD)

Drug Name
Brompheniramine
Synonyms
Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Seasonal allergic rhinitis CA08.01 Approved [2]
Urticaria EB00-EB05 Approved [2]
Vasomotor/allergic rhinitis CA08 Approved [2]
Pruritus EC90 Investigative [2]
Therapeutic Class
Antiallergic Agents
Affected Organisms
Humans and other mammals
ATC Code
R06AB01: Brompheniramine
R06AB: Substituted alkylamines
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 319.24
Logarithm of the Partition Coefficient (xlogp) 3.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract []
Bioavailability
89% of drug becomes completely available to its intended biological destination(s) [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C16H19BrN2
IUPAC Name
3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
Canonical SMILES
CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
InChIKey
ZDIGNSYAACHWNL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
6834
ChEBI ID
CHEBI:3183
CAS Number
86-22-6
UNII
H57G17P2FN
DrugBank ID
DB00835
TTD ID
D08VXO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Brompheniramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [5]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Brompheniramine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [5]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Brompheniramine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [6]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [5]
Coadministration of a Drug Treating the Disease Different from Brompheniramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Brompheniramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Brompheniramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Brompheniramine and Memantine. Alzheimer disease [8A20] [5]
Rivastigmine DMG629M Moderate Antagonize the effect of Brompheniramine when combined with Rivastigmine. Alzheimer disease [8A20] [7]
Donepezil DMIYG7Z Moderate Antagonize the effect of Brompheniramine when combined with Donepezil. Alzheimer disease [8A20] [7]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Brompheniramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [5]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Brompheniramine and Cariprazine. Bipolar disorder [6A60] [5]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Brompheniramine and Loperamide. Bowel habit change [ME05] [8]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Brompheniramine when combined with Acetylcholine. Cataract [9B10] [9]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [10]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Brompheniramine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [10]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Brompheniramine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [10]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Brompheniramine and Ethanol. Cystitis [GC00] [11]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Brompheniramine and Cyclobenzaprine. Depression [6A70-6A7Z] [5]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Brompheniramine and Isocarboxazid. Depression [6A70-6A7Z] [12]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Brompheniramine and OPC-34712. Depression [6A70-6A7Z] [5]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Brompheniramine and Clomipramine. Depression [6A70-6A7Z] [5]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Brompheniramine and Doxepin. Depression [6A70-6A7Z] [6]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Brompheniramine and Maprotiline. Depression [6A70-6A7Z] [5]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Brompheniramine and Esketamine. Depression [6A70-6A7Z] [13]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Brompheniramine and Mepenzolate. Digestive system disease [DE2Z] [5]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Brompheniramine and Oxybutynine. Discovery agent [N.A.] [5]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Brompheniramine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [14]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Brompheniramine and Diphenhydramine. Episodic vestibular syndrome [AB31] [5]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Brompheniramine and Solifenacin. Functional bladder disorder [GC50] [5]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Tolterodine. Functional bladder disorder [GC50] [5]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Brompheniramine when combined with Pilocarpine. Glaucoma [9C61] [9]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Brompheniramine and Procarbazine. Hodgkin lymphoma [2B30] [12]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Brompheniramine and Belladonna. Infectious gastroenteritis/colitis [1A40] [5]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Amantadine. Influenza [1E30-1E32] [15]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Brompheniramine and ITI-007. Insomnia [7A00-7A0Z] [5]
Physostigmine DM2N0TO Moderate Antagonize the effect of Brompheniramine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [7]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Brompheniramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [16]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Brompheniramine and Lasmiditan. Migraine [8A80] [17]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Brompheniramine and Flibanserin. Mood disorder [6A60-6E23] [18]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Brompheniramine and Thalidomide. Multiple myeloma [2A83] [19]
Ozanimod DMT6AM2 Moderate Additive CNS depression effects by the combination of Brompheniramine and Ozanimod. Multiple sclerosis [8A40] [12]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Brompheniramine and Phenindamine. Nasopharyngitis [CA00] [5]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Dimenhydrinate. Nausea/vomiting [MD90] [5]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Brompheniramine and Promethazine. Nausea/vomiting [MD90] [5]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Brompheniramine and Cyclizine. Nausea/vomiting [MD90] [5]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Brompheniramine and Apraclonidine. Optic nerve disorder [9C40] [20]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Brompheniramine and Flavoxate. Pain [MG30-MG3Z] [5]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Brompheniramine and Orphenadrine. Parkinsonism [8A00] [5]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Brompheniramine and Methylscopolamine. Peptic ulcer [DA61] [5]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Brompheniramine and Levomepromazine. Psychotic disorder [6A20-6A25] [5]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Brompheniramine and Quetiapine. Schizophrenia [6A20] [5]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Brompheniramine and Mesoridazine. Schizophrenia [6A20] [5]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Brompheniramine and Aripiprazole. Schizophrenia [6A20] [5]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Brompheniramine and Iloperidone. Schizophrenia [6A20] [5]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Brompheniramine and Paliperidone. Schizophrenia [6A20] [5]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Brompheniramine and Perphenazine. Schizophrenia [6A20] [5]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Brompheniramine and Molindone. Schizophrenia [6A20] [5]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Thiothixene. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Brompheniramine and Asenapine. Schizophrenia [6A20] [5]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Brompheniramine and Pimozide. Schizophrenia [6A20] [5]
⏷ Show the Full List of 56 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7133).
2 Brompheniramine FDA Label
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14.
5 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
6 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
7 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
8 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
9 Multum Information Services, Inc. Expert Review Panel.
10 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
11 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
12 Canadian Pharmacists Association.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
15 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
16 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
17 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
18 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
19 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
20 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.